Complete Response Letter Issued to Eflapegrastim for Chemotherapy-Induced Neutropenia Indication

Article

The makers of eflapegrastim received a complete response letter from the FDA due to concerns over manufacturing.

A biologics license application for the novel long-acting granulocyte-colony stimulating factor (G-CSF) agent eflapegrastim (Rolontis) was issued a complete response letter by the FDA due to deficiencies in manufacturing, as reported by the company responsible for the agent, Spectrum Pharmaceuticals.1

The FDA indicated that a reinspection will be necessary and further clarification regarding these plans are being discussed between the 2 entities.

“We are disappointed with this outcome and look forward to fully understanding the remediation timelines for the program,” Joe Turgeon, president and CEO of Spectrum Pharmaceuticals, said in a press release. “We continue to believe in Rolontis and plan to diligently complete the regulatory process to bring Rolontis to market.”

Eflapegrastim is intended for use alongside myelosuppressive anticancer drugs and, if approved, would be the first novel G-CSF agent to become available to clinicians and their patients in over a decade. The BLA was supported by data from 2 phase 3 clinical trials investigating the safety and efficacy of the agent in patients with early-stage breast cancer receiving chemotherapy for their disease.

In the ADVACNE trial (NCT02643420), eflapegrastim was compared with pegfilgrastim in patients with early breast cancer who were receiving docetaxel and cyclophosphamide with a primary end point of severe neutropenia duration in cycle 1. In 406 patients in the intent-to-treat population, the mean duration of severe neutropenia (DSN) was 0.19 days (standard deviation [SD], 0.478) in the experimental arm vs 0.34 days (SD, 0.668) with pegfilgrastim and met the threshold for non-inferiority (95% CI, -0.260 to -0.035; P <.0001). Noninferiority was maintained across all 4 cycles.2

The RECOVER trial (NCT02953340) was conducted in a similar fashion to ADVANCE in 237 intent to treat patients, for which the mean DSN was 0.31 days (SD, 0.688) for eflapegrastim compared with 0.39 days (SD, 0.949) with standard pegfilgrastim (95% CI, -0.292 to 0.129; P <.0001), with noninferiority maintained across 4 cycles of therapy.3

In either trial, the statistical significance for additional end points such as time to absolute neutrophil count (ANC) recovery, depth of ANC nadir, and incidence of febrile neutropenia at cycle 1 were noted.

This BLA for eflapegrastim was initially submitted in October 2019, which was an update to a previously withdrawn application for this indication. The new BLA had additional information in the Chemistry, Manufacturing and Controls (CMC) section regarding the manufacturing process.4 In December 2019, the company announced that the new BLA had been accepted by the FDA with a prescription drug user fee act (PDUFA) date of October 24, 2020.5

References

1. Spectrum Pharmaceuticals receives complete response letter from FDA for Rolontis (eflapegrastim). News release. Spectrum Pharmaceuticals. August 6, 2021. Accessed August 6, 2021. https://bit.ly/3AiXbj2

2. Schwartzberg LS, Yang Z, Peguero JA, et al. Safety and efficacy of eflapegrastim in reducing severe neutropenia in patients treated with myelosuppressive chemotherapy in a phase 3 randomized controlled trial compared to pegfilgrastim (ADVANCE trial). J Clin Oncol. 2018;36(suppl 15):e12513. doi:10.1200/JCO.2018.36.15_suppl.e12513

3. Schwartzberg LS, Bhat G, Mezei K, et al. Efficacy and safety of eflapegrastim confirmed in reducing severe neutropenia in breast cancer patients treated with myelosuppressive chemotherapy in the second phase 3 randomized controlled multinational trial compared to pegfilgrastim (RECOVER trial). Cancer Res. 2019;79(suppl 4):P1-13-05. doi: 10.1158/1538-7445.SABCS18-P1-13-05.

4. Spectrum Pharmaceuticals announces submission to the U.S. Food and Drug Administration of updated biologics license application for Rolontis. News release. Spectrum Pharmaceuticals. Published October 24, 2019. Accessed August 6, 2021. https://bit.ly/3fDAhv0

5. Spectrum Pharmaceuticals provides pipeline update on late stage programs. News release. Spectrum Pharmaceuticals. Published December 26, 2019. Accessed August 6, 2021. https://bit.ly/2VtM8EF

Recent Videos
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to expect at the 43rd Annual Chemotherapy Foundation Symposium, such as new chemotherapeutics and targeted therapies.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Related Content
Rising cancer diagnoses in the US highlight urgent needs for improved oncology education, workforce distribution, and care infrastructure, especially in rural areas.

A Decline in the US Oncology Workforce: What Will the Next Decade Bring?

Julie M. Vose, MD, MBA
December 2nd 2025
Article

Rising cancer diagnoses in the US highlight urgent needs for improved oncology education, workforce distribution, and care infrastructure, especially in rural areas.

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD
November 24th 2025
Podcast

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.

PAS-004 was deemed safe and tolerable when given in 37 mg capsules, so the trial will proceed to administer the agent in 45 mg capsules.

Cohort 7 of Novel MEK Inhibitor Trial Completed for MAPK Pathway-Driven Tumors

Tim Cortese
November 25th 2025
Article

PAS-004 was deemed safe and tolerable when given in 37 mg capsules, so the trial will proceed to administer the agent in 45 mg capsules.

Experts discussed supportive care and why it should be integrated into standard oncology care.

How Supportive Care Methods Can Improve Oncology Outcomes

Declan Walsh, MD;Denise B. Reynolds, RD;Adam Friedman, MD, FAAD;Daniel C. McFarland, DO;Michelle Fingeret, PhD;Christian J. Nelson, PhD;William S. Breitbart, MD
November 10th 2025
Podcast

Experts discussed supportive care and why it should be integrated into standard oncology care.

Novel Agent Yields Promising Results in MAPK-Associated Solid Tumors

Novel Agent Yields Promising Results in MAPK-Associated Solid Tumors

Ariana Pelosci
November 21st 2025
Article

Partial responses and stable disease were observed with PAS-004 in patients with advanced solid tumors harboring RAS, NF1, or RAF mutations.

Results from the C-POST trial showed that cemiplimab improved DFS vs placebo in patients with CSCC at high risk of recurrence following surgery and radiation.

EC Approves Adjuvant Cemiplimab in CSCC at High Risk of Recurrence

Tim Cortese
November 20th 2025
Article

Results from the C-POST trial showed that cemiplimab improved DFS vs placebo in patients with CSCC at high risk of recurrence following surgery and radiation.